- Home
- CACI vs ROIV Comparison
CACI vs ROIV Comparison
Compare CACI & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CACI
- ROIV
- Stock Information
- Founded
- CACI 1962
- ROIV 2014
- Country
- CACI United States
- ROIV United Kingdom
- Employees
- CACI N/A
- ROIV N/A
- Industry
- CACI EDP Services
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- CACI Technology
- ROIV Health Care
- Exchange
- CACI Nasdaq
- ROIV Nasdaq
- Market Cap
- CACI 10.9B
- ROIV 8.6B
- IPO Year
- CACI 1979
- ROIV N/A
- Fundamental
- Price
- CACI $497.94
- ROIV $15.45
- Analyst Decision
- CACI Strong Buy
- ROIV Strong Buy
- Analyst Count
- CACI 14
- ROIV 4
- Target Price
- CACI $544.50
- ROIV $15.50
- AVG Volume (30 Days)
- CACI 191.0K
- ROIV 6.8M
- Earning Date
- CACI 10-22-2025
- ROIV 11-11-2025
- Dividend Yield
- CACI N/A
- ROIV N/A
- EPS Growth
- CACI 20.00
- ROIV N/A
- EPS
- CACI 22.32
- ROIV N/A
- Revenue
- CACI $8,627,824,000.00
- ROIV $23,233,000.00
- Revenue This Year
- CACI $9.97
- ROIV N/A
- Revenue Next Year
- CACI $5.29
- ROIV $281.14
- P/E Ratio
- CACI $22.02
- ROIV N/A
- Revenue Growth
- CACI 12.64
- ROIV N/A
- 52 Week Low
- CACI $318.60
- ROIV $8.73
- 52 Week High
- CACI $588.26
- ROIV $14.48
- Technical
- Relative Strength Index (RSI)
- CACI 60.46
- ROIV 82.82
- Support Level
- CACI $485.27
- ROIV $13.81
- Resistance Level
- CACI $498.89
- ROIV $14.48
- Average True Range (ATR)
- CACI 11.04
- ROIV 0.45
- MACD
- CACI 2.00
- ROIV 0.23
- Stochastic Oscillator
- CACI 98.72
- ROIV 86.19
About CACI CACI International Inc.
CACI International Inc is an information solutions and services provider, offering information solutions and services to its customers. The company's primary customers are agencies and departments of the U.S. government, which account for the vast majority of the firm's revenue. It provides information solutions and services supporting national security missions and government modernization for intelligence, defense, and federal civilian customers. Some of the services provided by the company are functional software development, data, and business analysis, IT operations support, naval architecture, and life cycle support intelligence among others. The company's operating segments are; Domestic operations and International operations. It derives key revenue from the Domestic segment.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.